Pharmacological studies of Bufexamac topically applied on the skin.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001623:Betamethasone / Q000494:pharmacology; D002351:Carrageenan; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005260:Female; D005446:Fluocinolone Acetonide / Q000494:pharmacology; D003368:Gossypium; D006099:Granuloma / Q000188:drug therapy; D006168:Guinea Pigs; D006877:Hydroxamic Acids; D008297:Male; D010653:Phenylbutazone / Q000494:pharmacology; D011817:Rabbits; D011833:Radiation Injuries, Experimental / Q000188:drug therapy; D051381:Rats; D012867:Skin / Q000187:drug effects*; D014466:Ultraviolet Rays / Q000009:adverse effects; D014945:Wound Healing / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D006877:Hydroxamic Acids; D005446:Fluocinolone Acetonide; D002351:Carrageenan; D001623:Betamethasone; D010653:Phenylbutazone